Abbott Laboratories' stock is down 5.99% in pre-market trading, hitting a 20-day low amid broader market gains, with the Nasdaq-100 up 0.88% and S&P 500 up 0.56%.
The company's Q4 2025 earnings report revealed a non-GAAP EPS of $1.50, beating expectations by $0.01, but revenue of $11.46 billion fell short by $340 million, reflecting challenges from increased competition. Despite the revenue miss, Abbott projects a strong adjusted diluted EPS for 2026 between $5.55 and $5.80, indicating confidence in future performance.
The mixed results have raised concerns among investors, leading to a decline in stock price despite the positive EPS outlook. Abbott's ability to navigate competitive pressures will be crucial for maintaining investor confidence moving forward.
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 148.11 USD with a low forecast of 136.00 USD and a high forecast of 169.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 148.11 USD with a low forecast of 136.00 USD and a high forecast of 169.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 106.050
Low
136.00
Averages
148.11
High
169.00
Current: 106.050
Low
136.00
Averages
148.11
High
169.00
Piper Sandler
Overweight
to
NULL
downgrade
$150 -> $135
2026-01-23
Reason
Piper Sandler
Price Target
$150 -> $135
AI Analysis
2026-01-23
downgrade
Overweight
to
NULL
Reason
Piper Sandler lowered the firm's price target on Abbott to $135 from $150 and keeps an Overweight rating on the shares. The firm notes the company reported Q4 results that missed on the topline and came in-line on adjusted EPS, with the majority of the top miss driven by the Nutrition business. While Piper concedes the report was disappointing, it still likes the set-up for FY2026 behind a couple of key product launches, the ongoing momentum in the medtech business, and with the headwinds in the diagnostics business set to largely abate.
Mizuho
Anthony Petrone
Neutral
downgrade
$140 -> $125
2026-01-23
Reason
Mizuho
Anthony Petrone
Price Target
$140 -> $125
2026-01-23
downgrade
Neutral
Reason
Mizuho analyst Anthony Petrone lowered the firm's price target on Abbott to $125 from $140 and keeps a Neutral rating on the shares following the Q4 report. The firm cut estimates following the print. With the most recent Nutritional setback, the call for portfolio repositioning is now back in focus, which presents optionality moving forward for the shares, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABT
Unlock Now
BTIG
Marie Thibault
Buy
downgrade
$145 -> $140
2026-01-23
Reason
BTIG
Marie Thibault
Price Target
$145 -> $140
2026-01-23
downgrade
Buy
Reason
BTIG analyst Marie Thibault lowered the firm's price target on Abbott to $140 from $145 and keeps a Buy rating on the shares. Shares were down in Thursday trading following the company's Q4 sales miss and underwhelming 2026 revenue outlook, and the reaction is understandable as nearly all segments underperformed Q4 expectations, the Devices business was not the bright spot it typically is, and the 2026 sales guide was below consensus, the analyst tells investors in a research note. The company is reducing its prices, using promotions, and will release new products this year, but first half is expected to remain weak for Nutrition, BTIG added.
Oppenheimer
Oppenheimer
Outperform
downgrade
$140 -> $132
2026-01-23
Reason
Oppenheimer
Oppenheimer
Price Target
$140 -> $132
2026-01-23
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Abbott to $132 from $140 and keeps an Outperform rating on the shares. The firm notes Abbott reported Q4 revenues of $11.46B, vs. its/consensus $11.77B/$11.80B estimates. Oppenheimer's constructive outlook assumes subsiding non-MedTech headwinds, easier comparisons in FY26, and top-line composite growth ticking up to low-double digits, along with EBIT margins.
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
